Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lovastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ITGB2 | P05107 | 2/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | ITGAL | P20701 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lovastatin SCHEMBL5063297 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL16750775 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL13865314 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340570 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL23468171 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL8291088 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL23636214 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340553 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340569 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A | |
| Lovastatin SCHEMBL21340572 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081413-A2 | METHODS AND SYSTEMS FOR DISCOVERY OF EMBEDDED TARGET GENES IN BIOSYNTHETIC GENE CLUSTERS | LIFEMINE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-108315265-A | High yield monascus purpureus aspergillus versicolor Av-2 bacterial strains and its application | 浙江师范大学 | 2018-07-24 | — | — | CN | disclosed |
| CN-105758983-A | Method for quickly and accurately screening biological active matters in microorganisms | 中国农业科学院生物技术研究所 | 2016-07-13 | — | — | CN | disclosed |
| EP-1810971-B1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-1606287-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-101475912-B | Red koji strain and use thereof | YUZHANG DING | 2011-04-20 | — | — | CN | disclosed |
| US-7741289-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | disclosed |
| US-20040180860-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | disclosed |
| CN-1425374-A | Composition for treating hyperlipemia | LUNAN PHARM CO LTD (CN) | 2003-06-25 | — | — | CN | disclosed |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2000069446-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-1999026657-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASE | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 1999-06-03 | — | — | WO | disclosed |
| CN-1174037-A | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases | ZHANG MAOLIANG (CN) | 1998-02-25 | — | — | CN | disclosed |
| WO-1994027629-A1 | METHOD TO CONTROL APPETITE AND TREAT OBESITY | MERCK & CO., INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0571502-A1 | PMN-DERIVED CR3 MODULATOR AND USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1992013865-A1 | PMN-DERIVED CR3 MODULATOR AND USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | PTPN6, PTPN1, PNLIP | HMGCR 53/4885CYP3A4 2328/4885LMNA 2598/4885 |
| US-20040180860-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | HMGCR 29/4885CYP3A4 566/4885LMNA 1078/4885 |
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | HMGCR 29/4885CYP3A4 566/4885LMNA 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.